In the prolonged follow-up of the KEYNOTE-024 study, first-line pembrolizumab monotherapy continued to outperform chemotherapy on OS in patients with previously untreated advanced NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) aberrations (19). This evidence concerns the gene EGFR and non-small cell lung carcinoma.